X

Trial Profile

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms ESSENCE
Sponsors Novo Nordisk

Most Recent Events

08 Jun 2024 Baseline characteristics, disease criteria and non-invasive tests data (part 1) of this trial population presented at the European Association for the Study of the Liver Congress 2024
28 May 2024 Planned primary completion date changed from 7 Mar 2029 to 25 Apr 2029.
28 Feb 2024 Planned End Date changed from 20 Jul 2029 to 25 Apr 2029.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com